Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

References

• Schweizer MT, Drake CG. Immunotherapy for prostate cancer: Recent developments and future challenges. Cancer Metastasis Rev. 2014;33(2–3):641-55. doi:10.1007/s10555-013-9479-8. PMID:24477411
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-9. doi:10.1038/nature10673. PMID:22193102
   PubMed Web of Science ®Google Scholar
• Kakarla S, Gottschalk S. CAR T cells for solid tumors: Armed and ready to go? Cancer J. 2014;20(2):151-5. doi:10.1097/PPO.0000000000000032. PMID:24667962
   PubMed Web of Science ®Google Scholar
• Hillerdal V, Essand M. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs. 2015;29(2):75-89. doi:10.1007/s40259-015-0122-9. PMID:25859858
   PubMed Web of Science ®Google Scholar
• Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: A Jekyll and Hyde molecule? Clin Cancer Res. 2010;16(14):3533-8. doi:10.1158/1078-0432.CCR-09-3169. PMID:20501618
   PubMed Web of Science ®Google Scholar
• Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95(4):1735-40. doi:10.1073/pnas.95.4.1735. PMID:9465086
   PubMed Web of Science ®Google Scholar
• Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19(10):1288-96. doi:10.1038/sj.onc.1203426. PMID:10713670
   PubMed Web of Science ®Google Scholar
• Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol. 2003;30(5):649-58. doi:10.1016/S0093-7754(03)00350-6. PMID:14571412
   PubMed Web of Science ®Google Scholar
• Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32(3):272-9. doi:10.1016/j.urolonc.2013.09.003. PMID:24321253
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-76. doi:10.1038/nrclinonc.2013.46. PMID:23546520
   PubMed Web of Science ®Google Scholar
• Sadelain M. CAR therapy: The CD19 paradigm. J Clin Invest. 2015;125(9):3392-400. doi:10.1172/JCI80010. PMID:26325036
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388-98. doi:10.1158/2159-8290.CD-12-0548. PMID:23550147
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol. 2015;27(6):466-74. doi:10.1097/CCO.0000000000000232. PMID:26352543
   PubMed Web of Science ®Google Scholar
• Abate-Daga D, Davila ML. CAR models: Next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. 2016;3:16014. doi:10.1038/mto.2016.14. PMID:27231717
   PubMed Web of Science ®Google Scholar
• Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75(17):3505-18. doi:10.1158/0008-5472.CAN-15-0139. PMID:26330164
   PubMed Web of Science ®Google Scholar
• Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165-74. doi:10.1182/blood-2012-06-438002. PMID:23243285
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028-38. doi:10.4049/jimmunol.180.10.7028. PMID:18453625
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75(17):3596-607. doi:10.1158/0008-5472.CAN-15-0159. PMID:26330166
   PubMed Web of Science ®Google Scholar
• van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499-509. doi:10.1038/nrd4597. PMID:26129802
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360-5. doi:10.1073/pnas.0813101106. PMID:19211796
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-64. doi:10.1038/mt.2009.83. PMID:19384291
   PubMed Web of Science ®Google Scholar
• Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, Chang WC, Bretzlaff W, Starr R, Priceman S, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23(4):757-68. doi:10.1038/mt.2014.208. PMID:25366031
   PubMed Web of Science ®Google Scholar
• Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125-35. doi:10.1158/2326-6066.CIR-14-0127. PMID:25212991
   PubMed Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153-64. doi:10.1158/1078-0432.CCR-13-0330. PMID:23620405
   PubMed Web of Science ®Google Scholar
• Kunkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol Res. 2015;3(4):368-79. doi:10.1158/2326-6066.CIR-14-0200. PMID:25576337
   PubMed Web of Science ®Google Scholar
• Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203-11. doi:10.1097/01.cji.0000161397.96582.59. PMID:15838376
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184(12):6938-49. doi:10.4049/jimmunol.0901766. PMID:20483753
   PubMed Web of Science ®Google Scholar
• Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology. 2014;3(11):e970027. doi:10.4161/21624011.2014.970027. PMID:25941599
   PubMed Web of Science ®Google Scholar
• Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010;37(8):1529-38. doi:10.1007/s00259-010-1433-1. PMID:20354850
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 2015;3(4):356-67. doi:10.1158/2326-6066.CIR-14-0186. PMID:25600436
   PubMed Web of Science ®Google Scholar
• Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59(19):5030-6. PMID:10519419
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW. Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol. 2010;184(8):4284-94. doi:10.4049/jimmunol.0903701. PMID:20220093
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-7. doi:10.1038/nature21405. PMID:28225754
   PubMed Web of Science ®Google Scholar
• Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415-28. doi:10.1016/j.ccell.2015.09.004. PMID:26461090
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-17. doi:10.1056/NEJMoa1407222. PMID:25317870
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581-90. doi:10.1038/nm.3838. PMID:25939063
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-51. doi:10.1038/mt.2010.24. PMID:20179677
   PubMed Web of Science ®Google Scholar
• Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007;67(10):1121-31. doi:10.1002/pros.20608. PMID:17492652
   PubMed Web of Science ®Google Scholar
• Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer. 2014;14:30. doi:10.1186/1471-2407-14-30. PMID:24438073
   PubMed Web of Science ®Google Scholar
• Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014;25(12):1003-12. doi:10.1089/hum.2013.209. PMID:24694017
   PubMed Web of Science ®Google Scholar
• Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578-90. doi:10.1158/0008-5472.CAN-15-2524. PMID:26979791
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-44. doi:10.1172/JCI83092. PMID:27454297
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhou NY, Federico LE, Xia L, O'Connor TR. Repair of cyclobutane pyrimidine dimers or dimethylsulfate damage in DNA is identical in normal or telomerase-immortalized human skin fibroblasts. Nucleic Acids Res. 2005;33(8):2475-85. doi:10.1093/nar/gki542. PMID:15863724
   PubMed Web of Science ®Google Scholar
• Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004;64(24):9027-34. doi:10.1158/0008-5472.CAN-04-3703. PMID:15604268
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, et al. T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101(4):1637-44. doi:10.1182/blood-2002-07-1989. PMID:12393484
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chinnasamy N, Morgan RA. Protein L: A novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med. 2012;10:29. doi:10.1186/1479-5876-10-29. PMID:22330761
   PubMed Web of Science ®Google Scholar